1037207-08-1

Basic information

• Product Name: 1H-Benzimidazole-1-carboxylic acid, 5-(bromomethyl)-, 1,1-dimethylethyl ester
• CAS NO: 1037207-08-1
• Molecular Weight: 311.178
• Mol File: 1037207-08-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole-1-carboxylic acid, 5-(bromomethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-1-carboxylic acid, 5-(bromomethyl)-, 1,1-dimethylethyl ester(1037207-08-1)
• EPA Substance Registry System: 1H-Benzimidazole-1-carboxylic acid, 5-(bromomethyl)-, 1,1-dimethylethyl ester(1037207-08-1)

Safety Data

• Hazardous Substances Data: 1037207-08-1(Hazardous Substances Data)

Usage

Molecular weight

304.24 g/mol

Structure

A benzimidazole ring with a carboxylic acid group, a bromomethyl group, and a tert-butyl ester group attached

Appearance

White or off-white crystalline solid

Solubility

Slightly soluble in water, soluble in common organic solvents such as ethanol, methanol, and acetonitrile

Melting point

165-170°C

Boiling point

Not applicable as it is a solid

Reactivity

Reacts with nucleophiles due to the presence of the bromomethyl group

Uses

As a reagent in organic synthesis, in the pharmaceutical and agrochemical industries for the synthesis of various bioactive compounds, and as an intermediate in the production of other organic chemicals. It also has potential applications in the field of medicinal chemistry for the development of new drugs.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 614-97-1 5-methylbenzimidazole 
• 863877-82-1 tert-butyl 6-methyl-1H-benzo[d]imidazole-1-carboxylate 
• 863877-81-0 tert-butyl 5-methyl-1H-benzo[d]imidazole-1-carboxylate 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.